智通财经网·2025-08-06 10:43Financial Performance - In the first half of 2025, the company's product revenue reached 17.36 billion yuan, a year-on-year increase of 45.8% [1] - Total operating revenue for the same period was 17.52 billion yuan, reflecting a 46.0% year-on-year growth [1] - The net profit attributable to the parent company was 450 million yuan [1] - As of the end of the reporting period, total assets amounted to 44.87 billion yuan, an increase of 4.8% from the beginning of the period [1] - Equity attributable to the parent company was 26.86 billion yuan, up 11.1% from the beginning of the period [1] Product Sales - Global sales of Baiyueze® (Zebutinib Capsules) totaled 12.53 billion yuan, marking a 56.2% year-on-year increase, solidifying its leadership in the hematologic oncology field [2] - Sales in the United States reached 8.96 billion yuan, a 51.7% increase, driven by strong demand across all indications and favorable net pricing [2] - European sales amounted to 1.92 billion yuan, up 81.4%, attributed to market share gains in major European markets including Germany, Italy, Spain, France, and the UK [2] - In China, sales were 1.19 billion yuan, a 36.5% increase, due to growth in approved indications [2] - Baizean® (Trelatuzumab Injection) generated sales of 2.64 billion yuan, reflecting a 20.6% year-on-year growth, driven by new indications included in medical insurance and increased hospital supply [2] - Baizean® maintains a leading market share in China's PD-1 market [2]